Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Approved
Current status date:
2022-05-16
Product name:
DEFERASIROX (TYPE J)
DIN:
02527359
Product Monograph/Veterinary Labelling:
Date:
2022-05-13
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
JUBILANT GENERICS LIMITED
1a, Sector 16a Institutional Area
Noida
Uttar Pradesh
India
201301
Class:
Human
Dosage form(s):
Tablet
Route(s) of administration:
Oral
Number of active ingredient(s):
1
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
64:00.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
V03AC03 DEFERASIROX
Active ingredient group (AIG) number:See footnote5
0151733005
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| DEFERASIROX | 180 MG |